Acuitas Therapeutics named one of BC’s Top Employers of 2025
Read
about Acuitas Therapeutics named one of BC’s Top Employers of 2025
PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
Read
about PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
Read
about PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
Read
about Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
Read
about Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
Acuitas Therapeutics Honoured With Philanthropic Award
Read
about Acuitas Therapeutics Honoured With Philanthropic Award
Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
Read
about Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
Read
about PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
Christopher Sweeney Named Executive Director, Intellectual Property
Read
about Christopher Sweeney Named Executive Director, Intellectual Property
Acuitas Poster Presentations at ASGCT Annual Meeting
Read
about Acuitas Poster Presentations at ASGCT Annual Meeting